Ultragenyx Pharmaceutical (RARE) Cost of Revenue (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Cost of Revenue data on file, last reported at $30.0 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 3.45% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $110.3 million, a 24.72% increase from a year earlier, with the FY2025 full-year figure at $109.0 million, up 41.56% from the prior year.
• Cost of Revenue for Q1 2026 stood at $30.0 million, up from $29.3 million in the prior quarter.
• Over the last five years, Cost of Revenue for RARE reached as high as $30.0 million in Q1 2026 and fell as low as $5.3 million in Q4 2022.
• Historically, Cost of Revenue has averaged $17.0 million across 5 years, with a median of $17.2 million in 2024.
• Across the five-year window, Cost of Revenue jumped 163.71% in 2022 and rose 3.45% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $5.3 million in 2022, then soared by 122.64% to $11.8 million in 2023, then surged by 44.96% to $17.2 million in 2024, then surged by 70.95% to $29.3 million in 2025, then gained by 2.23% to $30.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $30.0 million in Q1 2026, $29.3 million in Q4 2025, and $28.0 million in Q3 2025.